DURSUN, I. Et Al. 2016. Canakinumab is safe in the treatment of renal transplant patient having amyloidosis secondary to Hyper-IgD syndrome. 17th Congress of the International Pediatric Nephrology Association , (Iguaçu, Brazil), 1890.

DURSUN, I., SÖZERİ, B., PAÇ KISAARSLAN, A., DÜŞÜNSEL, R., POYRAZOĞLU, M. H., & GÜNDÜZ, Z., (2016). Canakinumab is safe in the treatment of renal transplant patient having amyloidosis secondary to Hyper-IgD syndrome . 17th Congress of the International Pediatric Nephrology Association (pp.1890). Iguaçu, Brazil

DURSUN, İSMAİL Et Al. "Canakinumab is safe in the treatment of renal transplant patient having amyloidosis secondary to Hyper-IgD syndrome," 17th Congress of the International Pediatric Nephrology Association, Iguaçu, Brazil, 2016

DURSUN, İSMAİL Et Al. "Canakinumab is safe in the treatment of renal transplant patient having amyloidosis secondary to Hyper-IgD syndrome." 17th Congress of the International Pediatric Nephrology Association , Iguaçu, Brazil, pp.1890, 2016

DURSUN, I. Et Al. (2016) . "Canakinumab is safe in the treatment of renal transplant patient having amyloidosis secondary to Hyper-IgD syndrome." 17th Congress of the International Pediatric Nephrology Association , Iguaçu, Brazil, p.1890.

@conferencepaper{conferencepaper, author={İSMAİL DURSUN Et Al. }, title={Canakinumab is safe in the treatment of renal transplant patient having amyloidosis secondary to Hyper-IgD syndrome}, congress name={17th Congress of the International Pediatric Nephrology Association}, city={Iguaçu}, country={Brazil}, year={2016}, pages={1890} }